Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Yoshiaki Murakami"'
Autor:
Yoshiaki Murakami, Shingo Seo, Hiroyuki Otsuka, Yasushi Hashimoto, Naru Kondo, Shinya Takahashi, Takeshi Sudo, Kenjiro Okada, Tatsuaki Sumiyoshi, Kenichiro Uemura
Publikováno v:
European Journal of Cancer. 159:215-223
Background The prognosis of patients with borderline resectable pancreatic cancer with arterial contact (BRPC-A) is extremely poor, and effective preoperative treatment is indispensable. We evaluated the clinical efficacy and safety of neoadjuvant ch
Autor:
Naru Kondo, Kenichiro Uemura, Tatsuaki Sumiyoshi, Kenjiro Okada, Shingo Seo, Hiroyuki Otsuka, Reo Kawano, Yoshiaki Murakami, Shinya Takahashi
Publikováno v:
Journal of hepato-biliary-pancreatic sciencesREFERENCES. 29(8)
The aim of this study was to assess whether the duration of adjuvant gemcitabine plus S-1 (GS) chemotherapy has any effect on survival in patients with pancreatic ductal adenocarcinoma (PDAC).Of the 290 patients who received adjuvant GS chemotherapy,
Autor:
Ryuta Shintakuya, Keisuke Okano, Naru Kondo, Taijiro Sueda, Shinya Takahashi, Kenichiro Uemura, Naoya Nakagawa, Yoshiaki Murakami
Publikováno v:
Pancreatology. 18:191-197
Although postoperative adjuvant chemotherapy for pancreatic ductal adenocarcinoma (PDAC) improves survival, its efficacy varies among individuals. Identification of biomarkers that can predict the efficacy of adjuvant chemotherapy for PDAC is essenti
Autor:
Shinya Takahashi, Taijiro Sueda, Takeshi Sudo, Kenjiro Okada, Yasushi Hashimoto, Naoya Nakagawa, Naru Kondo, Yoshiaki Murakami, Kenichiro Uemura
Publikováno v:
Cancer Chemotherapy and Pharmacology. 79:801-811
The survival benefit of neoadjuvant therapy for patients with borderline resectable pancreatic carcinoma has been reported recently. However, prognostic factors for this strategy have not been clearly elucidated. The aim of this study was to clarify
Autor:
Mariko Doi, Hiroki Yamaue, Ken-ichi Okada, Manabu Kawai, Suguru Yamada, Yoshiaki Murakami, Ippei Matsumoto, Sohei Satoi, Toshio Shimokawa, Seiko Hirono, Masayuki Sho, Hidetoshi Eguchi
Publikováno v:
Oncology. 93:343-346
We conducted a prospective multicenter phase II trial of patients with borderline resectable pancreatic carcinoma to investigate the efficacy of neoadjuvant nab-paclitaxel plus gemcitabine therapy on overall survival (OS). The clinical trial primaril
Autor:
Kenichiro Uemura, Yoshiaki Murakami, Shinya Takahashi, Taijiro Sueda, Naru Kondo, Ryuta Shintakuya, Yasushi Hashimoto, Naoya Nakagawa
Publikováno v:
Journal of Surgical Oncology. 113:405-412
Background and Objectives The aim of this study was to evaluate the efficacy of adjuvant gemcitabine plus S-1(GS) chemotherapy for pancreatic carcinoma patients, stratified by the National Comprehensive Cancer Network (NCCN) preoperative resectabilit
Publikováno v:
Gastroenterology. 158:S-1529
Autor:
Fuminori Sonohara, Tsutomu Fujii, Yasuhiro Kodera, Masamichi Hayashi, Fuyuhiko Motoi, Suguru Yamada, Mitsugu Sekimoto, Sohei Satoi, Kazuto Shibuya, So Yamaki, Hideki Takami, Yoshiaki Murakami, Satoshi Hirano, Isaku Yoshioka, Hitoshi Inoue, Tomohisa Yamamoto
Publikováno v:
Journal of Clinical Oncology. 38:702-702
702 Background: Pancreatic ductal adenocarcinoma (PDAC) patients with peritoneal metastasis (peritoneal deposits and/or positive peritoneal cytology) have an extremely poor prognosis, and an effective treatment strategy remains elusive. Methods: The
Autor:
Naru Kondo, Kenichiro Uemura, Yoshiaki Murakami, Taijiro Sueda, Shinya Takahashi, Naoya Nakagawa, Kenjiro Okada
Publikováno v:
Journal of surgical oncology. 118(7)
Background and objectives The aim of this study was to investigate the prognostic impact of postoperative complications after pancreatoduodenectomy (PD) for pancreatic ductal adenocarcinoma (PDAC) stratified by resectability status. Methods Medical r
Autor:
Shinya Takahashi, Taijiro Sueda, Yoshiaki Murakami, Naoya Nakagawa, Naru Kondo, Kenichiro Uemura, Kazuhiro Toyota
Publikováno v:
Annals of surgical oncology. 25(5)
Hu-antigen R (HuR) is an RNA-binding protein that regulates the stability, translation, and nucleus-to-cytoplasm translocation of messenger RNAs (mRNAs). The aim of this study was to investigate the prognostic significance of HuR in cholangiocarcinom